By Anang Endaryanto, Zahrah Hikmah, Ariyanto Harsono
Objective: To evaluate the efficacy of superoxide dismutase (SOD) in lungfunction (FEV1 reversibility) and respiratory symptoms (drug scores,symptoms scores) in asthmatic and house dust mite allergic children receivinghouse dust mites immunotherapy.
Methods: Forty subjects aged 6–17 years old with asthma, tested positive forhouse dust mite allergy on skin prick test, and received immunotherapy wereenrolled in this study. All subjects completed clinical based assessments anddiary-based assessments for drug and symptom scores. Following a four-weekbaseline assessment, all subjects were randomized to receive SOD or placebo.Respiratory symptoms (drug and symptoms score) and FEV1 were evaluated at the end of the 1st, 2nd, 3rd, and 4th weeks after randomization. Drug score,symptoms score, and FEV1 reversibility test results were analyzed using aPaired t test and repeated measure of ANOVA.
Results: There was a significant difference in drug scores, symptoms score,and FEV1 reversibility test outcomes between SOD and placebo. SOD groupshowed a significant decrease in all outcome measures compared to those inplacebo group.
Conclusions: The use of SOD as antioxidants is effective in acceleratingsymptom relief for children with asthma and house dust mite allergy receivinghouse dust mite immunotherapy.